Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WockhardtNSE:WOCKPHARMA -0.63%58 Days Payable is 161.55 as of Mar. 2026, which is 25% below its 10-year median of 214.12. GuruFocus rates NSE:WOCKPHARMA with a GF Score™ of 58/100 and a GF Value™ of ₹1,247.56 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 925 Drug Manufacturers companies, Wockhardt ranks better than 82.7% on this metric.
Wockhardt's average Accounts Payable for the
three
months ended in Mar. 2026 was ₹5,630 Mil. Wockhardt's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹3,180 Mil.
Hence, Wockhardt's Days Payable for the
three
months ended in Mar. 2026 was 161.55.
The historical rank and industry rank for Wockhardt's Days Payable or its related term are showing as below:
NSE:WOCKPHARMA'
s Days Payable Range Over the Past 10 Years
Min: 113.12 Med: 214.12 Max: 281.54
Current: 187.23
During the past 13 years, Wockhardt's highest Days Payable was 281.54. The lowest was 113.12. And the median was 214.12.
NSE:WOCKPHARMA's Days Payable is ranked better than 82.7% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs NSE:WOCKPHARMA: 187.23
Wockhardt's Days Payable
declined
from Mar. 2025 (207.77) to Mar. 2026 (161.55).
It may suggest that Wockhardtaccelerated paying its suppliers.
Wockhardt Days Payable Related Terms
Wockhardt Days Payable Historical Data
* Premium members only.
The historical data trend for Wockhardt's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WOCKPHARMA vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wockhardt Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wockhardt's Days Payable distribution charts can be found below:
* The bar in red indicates where Wockhardt's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Wockhardt's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wockhardt (NSE:WOCKPHARMA) has a Days Payable of 161.55 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wockhardt and its competitors. This is 25% below median its historical median of 214.12. Over the past decade, Wockhardt's Days Payable has ranged from 113.12 to 281.54. According to the industry distribution chart, Wockhardt ranks #160 out of 925 companies in the Drug Manufacturers industry, placing it in the top 17.3%.
Is Wockhardt's Days Payable too high?
Wockhardt's current Days Payable of 161.55 is 25% below median its 10-year median of 214.12. Over the past 10 years, this metric has ranged from a low of 113.12 to a high of 281.54. The Drug Manufacturers industry median Days Payable is 90.38. Wockhardt's value of 161.55 is 78.7% above this industry median. Based on the distribution chart, Wockhardt ranks #160 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wockhardt has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wockhardt ranks #160 out of 925 companies for Days Payable. This places Wockhardt in the top 17% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Wockhardt's value of 161.55 is 78.7% above this benchmark. Historically, Wockhardt's own Days Payable has ranged from 113.12 to 281.54 over the past decade. While the company's 10-year median is 214.12 vs. the industry median of 90.38, Wockhardt has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wockhardt's current Days Payable of 161.55 is 78.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wockhardt and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wockhardt's current Days Payable is 161.55, which is 25% below median its own 10-year median of 214.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,247.56, compared to a current price of ₹1,849.70 — trading 48.3% above its estimated fair value. The current Days Payable is 161.55, which is 25% below median its 10-year median of 214.12 and 78.7% above the Drug Manufacturers industry median of 90.38. Wockhardt's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current Days Payable is 161.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued.
The current stock price of ₹1,849.70 is trading 48.3% above its estimated GF Value™ of ₹1,247.56.
GuruFocus considers Wockhardt to be Significantly Overvalued.
Key valuation signals for NSE:WOCKPHARMA:
Days Payable: 161.55 (25% below median its 10-year median of 214.12)
GF Value™: ₹1,247.56 vs. price of ₹1,849.70 (48.3% above fair value)
Industry Position: 78.7% above the Drug Manufacturers median (#160 of 925)
No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
58GF Score
Get the complete analysis for NSE:WOCKPHARMA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WOCKPHARMA has been successfully added to your 
